When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Primary invasive breast cancer

Последний просмотренный: 22 Oct 2026
Last updated: 23 Jul 2026
23 Jul 2026

Imaging-based artificial intelligence (AI) models for breast cancer risk assessment added to US guidelines

Updated breast cancer screening and diagnosis guidelines from the National Comprehensive Cancer Network (NCCN) now include the use of validated imaging-based AI risk assessment models to determine risk of breast cancer, and strategies for screening and risk-reduction.

The imaging-based AI risk assessment models can be used to analyze negative screening mammograms to detect subtle tissue patterns associated with future malignancy, from which they generate a risk assessment score.

The NCCN guideline recommends increased risk screening follow-up for women with an AI-generated 5-year risk for invasive breast cancer ≥1.7%. Increased risk screening follow-up includes annual mammography with tomosynthesis, discussion of risk reduction strategies, and consideration of supplemental imaging, which should start at the age when increased risk is identified. Women assessed using a validated imaging-based AI risk model should be re-evaluated periodically, because their risk may change over time.

Clinical risk prediction models are widely used in current practice; however, these may overestimate or underestimate risk or be unsuitable for certain groups. One systematic review reported similar or improved discriminatory accuracy with mammography-based AI risk models compared with risk based on breast density or clinical risk prediction models.[113]​

Further prospective studies are needed to fully determine the role of imaging-based AI risk assessment models in breast cancer risk assessment and screening.

Смотрите Диагностика: скрининг

Оригинальный источник обновления

Резюме

Определение

Анамнез и осмотр

Ключевые диагностические факторы

  • breast mass
  • nipple discharge
  • axillary lymphadenopathy
Полная информация

Другие диагностические факторы

  • skin thickening or discoloration
  • retraction, inversion, or scaling of the nipple
Полная информация

Факторы риска

  • increasing age
  • female sex
  • ethnic origin
  • positive family history of breast and/or other cancers
  • genetic mutations in breast cancer susceptibility genes
  • endogenous estrogen exposure
  • exogenous estrogen/progestin exposure
  • alcohol consumption
  • radiation exposure
  • atypical breast disease
  • increased breast density
  • mild, moderate, or marked background parenchymal enhancement (BPE) on breast magnetic resonance imaging (MRI)
  • reduced physical activity
  • poor diet
  • high socioeconomic status
  • smoking
  • obesity
  • high dibutyl-phthalate exposure
Полная информация

Диагностические исследования

Исследования, которые показаны в первую очередь

  • mammogram
Полная информация

Исследования, проведение которых нужно рассмотреть

  • breast ultrasound
  • breast MRI
  • biopsy
  • hormone receptor testing
  • HER2 testing
  • gene expression assays
  • computed tomography
  • bone scan
  • genetic testing
  • CBC
  • LFTs
  • alkaline phosphatase
Полная информация

Алгоритм лечения

Острый

early-stage breast cancer (stages I to IIB [T2 N1 M0])

locally advanced breast cancer (stages IIB [T3 N0 M0] to III)

ПРОДОЛЖЕНИЕ

disease recurrence

Составители

Авторы

Kandace P. McGuire, MD

Professor of Surgery

Virginia Commonwealth University

Richmond, VA

Раскрытие информации

KPM is on the Advisory Board for Kubtec and the speaker bureau for Endomag/Hologic.

Выражение благодарностей

Dr Kandace McGuire would like to gratefully acknowledge Dr Krystal Cascetta, Professor Amy Tiersten, Dr Hope S. Rugo, Dr Amal Melhem-Bertrandt, Dr Gabriel N. Hortobagyi, and Dr Phuong Khanh H. Morrow, the previous contributors to this topic.

Раскрытие информации

KC, AMB, GNH, and PKHM declare that they have no competing interests. AT is on the advisory board for Immunomedics, AstraZeneca, Novartis, Eisai, and Healthline; receives research funding from Pfizer, Novartis, Genentech, Lilly, and AstraZeneca; and does expert testimony work. HSR receives research funding through the University of California from Novartis, Pfizer, Genentech, Macrogenics, Plexxikon, Merck, Nektar, and GSK; has been reimbursed for travel by Novartis, Genentech, and Nektar; and has received speaker honorarium from Genomic Health.

Рецензенты

Savannah Liddell, MD

Fellow

Mayo Clinic College of Medicine and Science

Rochester, MN

Раскрытие информации

SL declares that she has no competing interests.

Katherine H.R. Tkaczuk, MD, FACP

Professor of Medicine

University of Maryland School of Medicine

Baltimore, MD

Раскрытие информации

KHRT declares that she has no competing interests.

Susan Tannenbaum, MD

Associate Professor, Medicine

Chief, Division of Hematology/Oncology

Medical Director, Neag Comprehensive Cancer Center

University of Connecticut

Farmington, CT

Раскрытие информации

ST declares that she has no competing interests.

Emily Hsu, MD

Fellow

Division of Hematology/Oncology

University of Connecticut

Farmington, CT

Раскрытие информации

EH declares that she has no competing interests.

Anees Chagpar, MD

Assistant Professor

University of Louisville

Louisville, KY

Раскрытие информации

AC declares that she has no competing interests.

Gurhan Celik, MD

General Surgeon

General Surgery Department

Istanbul Training and Research Hospital

Istanbul

Turkey

Раскрытие информации

GC is an author of a number of references cited in this topic.

Edward R. Sauter, MD, PhD

Medical Officer

Breast and Gynecologic Cancer Working Group

Division of Cancer Prevention

National Cancer Institute

Bethesda, MD

Раскрытие информации

ERS declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

Список литературы

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Основные статьи

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis [internet publication].Полный текст

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer [internet publication].Полный текст

Loibl S, André F, Bachelot T, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024 Feb;35(2):159-82.Полный текст  Аннотация

Denduluri N, Somerfield MR, Eisen A, et al. Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2)-negative and adjuvant targeted therapy for HER2-positive breast cancers: an American Society of Clinical Oncology guideline adaptation of the Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2016 Jul 10;34(20):2416-27.Полный текст  Аннотация

Park KU, Somerfield MR, Anne N, et al. Sentinel lymph node biopsy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2025 May 10;43(14):1720-41.Полный текст  Аннотация

Статьи, указанные как источники

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

Использование этого контента попадает под действие нашего заявления об отказе от ответственности